



Press release, September 5, 2025

ASSET partnership, coordinated by Diamyd Medical, organizes 2nd annual Type 1 Diabetes screening conference

Diamyd Medical, as coordinating member of the ASSET innovation partnership, is pleased to announce a new edition of the conference on the future of screening, early detection and prevention of Type 1 Diabetes. The conference is hosted by the ASSET partner Leading Healthcare Foundation on October 9th, 2025, in Stockholm, Sweden. The conference is co-sponsored by Sanofi.

“Precision diagnostics, early screening and preventive medicine must be top priorities in today’s healthcare. Achieving this is going to require a lot of work and rethinking of old positions, and this conference, along with the ASSET partnership, plays an important part in driving that change”, says Hans Winberg, General Secretary of the Leading Healthcare Foundation.

Following the success of last year's event with approximately 100 in-person attendees, ASSET is organizing a new edition of this conference aimed at healthcare professionals, decision-makers, researchers, representatives from the life science industry, patient organizations and politicians.

The program includes three keynote speakers, Prof. Ola Bratt (Göteborgs universitet), Dr. Daniel Agardh (Lunds Universitet & DiaUnion) and Dr. Frida Sundberg (Universitetssjukhuset Örebro & ASSET) and is focused on how early detection and precision prevention of type 1 diabetes can be introduced into the Swedish healthcare system, including lessons-learned from other therapeutic areas.

“The engagement of all partners involved in this innovation project has allowed ASSET to become a platform for policy discussions around early diagnosis and precision prevention for type 1 diabetes. Organizing this conference series, together with our ASSET partners and Sanofi is another key step in this direction” says Ulf Hannelius, CEO of Diamyd Medical.

For more details and to register for the event, please visit <https://leadinghealthcare.se/kalendern/implementering-av-framtidens-screening/>.

About ASSET

The innovation milieu ASSET (AI for Sustainable Prevention of Autoimmunity in the Society) is an industry-healthcare partnership including Mainly AI, Lund University, Sahlgrenska University Hospital, Örebro University Hospital, The Swedish National Diabetes Register, Leading Health Care Foundation and Diamyd Medical, project coordinator. The project started in September 2021, has a duration of five years, and is financed by the Swedish innovation agency VINNOVA.

ASSET has three main goals: Predict, Prevent and Implement.

Predict: evaluate new algorithms based on Artificial Intelligence (AI) to be able to assess the individual risk of developing Type 1 Diabetes (T1D), and the likelihood of responding to different treatments. Data from cohort studies such as TEDDY (The Environmental Determinants of Diabetes in the Young), from Diamyd Medical's clinical trials with Diamyd® and from sources such as the National Diabetes Registry will constitute the initial training dataset for the algorithm. T1D will form the pilot project for the program, but the goal is extending the functionality to other indications including other autoimmune diseases that are strongly linked to T1D such as celiac disease (gluten intolerance) and autoimmune thyroiditis (inflammatory disease of the thyroid gland).

Prevent: ASSET aims to be a test-bed for clinical development, with a pilot trial ongoing testing a precision medicine approach to early stage T1D.

Implement: ASSET will study organizational, economic, and legal prerequisites and consequences of applying the approach as a tool for precision health in the Swedish health care system. The goal is to proactively manage obstacles that can slow down the implementation and spread of the innovations in the healthcare system.

Website: <https://www.asset.healthcare>

About Diamyd Medical

Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes. Diamyd® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial with potential for an accelerated approval pathway in the US is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results in preserving endogenous insulin production have previously been shown in a large genetically predefined patient group – both in a largescale meta-analysis as well as in the Company's prospective European Phase IIb trial. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

For further information, please contact:

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)

Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68

E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

The information was provided by the contact person above, for publication at 13:00 CET, September 5, 2025.